A Phase 3 interventional study of BG00012 and Placebo in Relapsing-Remitting Multiple Sclerosis, sponsored by Biogen. Completed at 160 sites in 29 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2015-01-26.
Sponsored by Biogen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 3rd largest by enrollment, is one of 2 that started in 2007, is one of 10 in phase 3, and was the 1st registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2007.
This study's enrollment of 1,234 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 61 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 5 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen: none open now, 1 under way, 1 of them phase 3. Of 72 finished, 31 (43%) have results posted.
Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, this one is the 5th largest by enrollment of the 59 interventional ones that give a count, is one of 5 that started in 2007, is one of 25 in phase 3, and was the 9th registered.
Biogen’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Biogen’s 78 in Multiple Sclerosis, Relapsing-Remitting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get worse.
The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated. Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received two placebo capsules orally three times daily (TID)
Drug: Placebo
Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
Drug: BG00012
Participants received two 120 mg BG00012 capsules orally three times daily (TID)
Drug: BG00012
Also known as: dimethyl fumarate, Tecfidera®
Proportion of Subjects Relapsed
A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurolgic evaluation committee. The proportion of subjects with a relapse was estimated using the Kaplan-Meier method, which was based on the time-to-first-relapse survival distribution.
Time frame: 2 years
Number of New or Newly Enlarging T2 Hyperintense Lesions
The number of new or newly enlarging T2 hyperintense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T2 lesion count were calculated from a negative binomial regression model adjusted for region and baselineT2 lesion volume
Time frame: 2 years
Number of Gadolinium-enhancing T1-weighted Lesions
The number of Gd-enhancing lesions was assessed using brain MRI scans following administration of gadolinium, a contrast agent. The mean number of Gd-enhancing lesions at 2 years was the average of the number of lesions at 2 years in a treatment group.
Time frame: 2 years
Number of Subjects With Gadolinium (Gd)-Enhancing Lesions
Note: This outcome measure represents the categorical analysis for the previously listed secondary outcome measure "Number of Gadolinium-enhancing T1-weighted lesions"
Time frame: 2 years
Annualized Relapse Rate
A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee. The adjusted annualized relapse rate was calculated from a negative binomial regression model, adjusted for baseline EDSS (≤ 2.0 vs. \>2.0), age (\<40 versus ≥40 years), region, and the number of relapses in the 1 year prior to enrollment.
Time frame: 2 years
Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS)
The EDSS is based on a standardized neurological examination and focuses on symptoms that commonly occur in MS. EDSS scores range from 0.0 (normal) to 10.0 (death due to MS). Disability progression was defined as ≥ 1.0 point increase in subjects with a baseline EDSS of ≥1.0, or a ≥1.5 point increase in subjects with a baseline EDSS = 0, and required that the increase from baseline was confirmed ≥12 weeks later. The proportion of subjects with confirmed (12-week) disability progression was estimated using the Kaplan-Meier method, which was based on the time-to-first-progression survival distribution.
Time frame: 2 years
Subjects were screened and enrolled at 198 investigational sites in 28 countries.
| Milestone | Placebo | BG00012 240 mg Twice Daily (BID) | BG00012 240 mg 3 Times Daily (TID) |
|---|---|---|---|
| Started | 408 | 410 | 416 |
| Completed | 317 | 315 | 320 |
| Not completed | 91 | 95 | 96 |
| Withdrew: Adverse event | 22 | 40 | 36 |
| Withdrew: Lost to follow-up | 9 | 11 | 11 |
| Withdrew: Withdrawal by subject | 31 | 22 | 19 |
| Withdrew: Physician decision | 4 | 4 | 3 |
| Withdrew: Protocol violation | 4 | 4 | 8 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Other-unspecified | 21 | 14 | 18 |
A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurolgic evaluation committee. The proportion of subjects with a relapse was estimated using the Kaplan-Meier method, which was based on the time-to-first-relapse survival distribution.
| Proportion of subjects,confirmed relapse | Placebo | BG00012 240 mg Twice Daily (BID) | BG00012 240 mg 3 Times Daily (TID) |
|---|---|---|---|
| Proportion of Subjects Relapsed | 0.461 | 0.270 | 0.260 |
The number of new or newly enlarging T2 hyperintense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T2 lesion count were calculated from a negative binomial regression model adjusted for region and baselineT2 lesion volume
| Number of lesions | Placebo | BG00012 240 mg BID | BG00012 240 mg TID |
|---|---|---|---|
| Number of New or Newly Enlarging T2 Hyperintense Lesions | 17.0 (12.9 to 22.4) | 2.6 (2.0 to 3.5) | 4.4 (3.2 to 5.9) |
The number of Gd-enhancing lesions was assessed using brain MRI scans following administration of gadolinium, a contrast agent. The mean number of Gd-enhancing lesions at 2 years was the average of the number of lesions at 2 years in a treatment group.
| Number of lesions | Placebo | BG00012 240 mg BID | BG00012 240 mg TID |
|---|---|---|---|
| Number of Gadolinium-enhancing T1-weighted Lesions | 1.8 ± 4.15 | 0.1 ± 0.63 | 0.5 ± 1.73 |
Note: This outcome measure represents the categorical analysis for the previously listed secondary outcome measure "Number of Gadolinium-enhancing T1-weighted lesions"
| Number of subjects | Placebo | BG00012 240 mg Twice Daily (BID) | BG00012 240 mg 3 Times Daily (TID) |
|---|---|---|---|
| 0 lesions | 103 | 142 | 130 |
| 1 lesion | 16 | 8 | 10 |
| 2 lesions | 13 | 1 | 2 |
| 3-4 lesions | 15 | 0 | 3 |
| >=5 lesions | 18 | 1 | 7 |
A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee. The adjusted annualized relapse rate was calculated from a negative binomial regression model, adjusted for baseline EDSS (≤ 2.0 vs. \>2.0), age (\<40 versus ≥40 years), region, and the number of relapses in the 1 year prior to enrollment.
| Relapses per year | Placebo | BG00012 240 mg BID | BG00012 240 mg TID |
|---|---|---|---|
| Annualized Relapse Rate | 0.364 (0.303 to 0.436) | 0.172 (0.138 to 0.214) | 0.189 (0.153 to 0.234) |
The EDSS is based on a standardized neurological examination and focuses on symptoms that commonly occur in MS. EDSS scores range from 0.0 (normal) to 10.0 (death due to MS). Disability progression was defined as ≥ 1.0 point increase in subjects with a baseline EDSS of ≥1.0, or a ≥1.5 point increase in subjects with a baseline EDSS = 0, and required that the increase from baseline was confirmed ≥12 weeks later. The proportion of subjects with confirmed (12-week) disability progression was estimated using the Kaplan-Meier method, which was based on the time-to-first-progression survival distribution.
| Proportion of participants | Placebo | BG00012 240 mg BID | BG00012 240 mg TID |
|---|---|---|---|
| Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS) | 0.271 | 0.164 | 0.177 |
Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 86/408 (21.1%) | 384/408 (94.1%) |
| BG00012 240 mg Twice Daily (BID) | — | 74/410 (18%) | 394/410 (96.1%) |
| BG00012 240 mg 3 Times Daily (TID) | — | 65/416 (15.6%) | 393/416 (94.5%) |
| Total BG00012 | — | 139/826 (16.8%) | 787/826 (95.3%) |
| Event | Placebo | BG00012 240 mg Twice Daily (BID) | BG00012 240 mg 3 Times Daily (TID) | Total BG00012 |
|---|---|---|---|---|
| Multiple Sclerosis RelapseNervous system disorders | 60/408 | 39/410 | 32/416 | 71/826 |
| GastroenteritisInfections and infestations | 0/408 | 4/410 | 1/416 | 5/826 |
| GastritisGastrointestinal disorders | 0/408 | 0/410 | 3/416 | 3/826 |
| Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/408 | 0/410 | 1/416 | 1/826 |
| DepressionPsychiatric disorders | 2/408 | 1/410 | 0/416 | 1/826 |
| Tendon RuptureInjury, poisoning and procedural complications | 2/408 | 0/410 | 0/416 | 0/826 |
| PneumoniaInfections and infestations | 1/408 | 2/410 | 0/416 | 2/826 |
| GoitreEndocrine disorders | 0/408 | 1/410 | 2/416 | 2/826 |
| HeadacheNervous system disorders | 0/408 | 0/410 | 2/416 | 2/826 |
| Ovarian CystReproductive system and breast disorders | 1/408 | 1/410 | 2/416 | 3/826 |
| Event | Placebo | BG00012 240 mg Twice Daily (BID) | BG00012 240 mg 3 Times Daily (TID) | Total BG00012 |
|---|---|---|---|---|
| MULTIPLE SCLEROSIS RELAPSENervous system disorders | 181/408 | 109/410 | 107/416 | 216/826 |
| FLUSHINGVascular disorders | 20/408 | 153/410 | 132/416 | 285/826 |
| NASOPHARYNGITISInfections and infestations | 101/408 | 108/410 | 109/416 | 217/826 |
| HEADACHENervous system disorders | 80/408 | 81/410 | 78/416 | 159/826 |
| DIARRHEAGastrointestinal disorders | 55/408 | 62/410 | 78/416 | 140/826 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 53/408 | 63/410 | 51/416 | 114/826 |
| FATIGUEGeneral disorders | 54/408 | 57/410 | 63/416 | 120/826 |
| BACK PAINMusculoskeletal and connective tissue disorders | 57/408 | 59/410 | 46/416 | 105/826 |
| URINARY TRACT INFECTIONInfections and infestations | 53/408 | 55/410 | 54/416 | 109/826 |
| NAUSEAGastrointestinal disorders | 38/408 | 53/410 | 54/416 | 107/826 |
| Age, Continuous(Years) | Placebo | BG00012 240 mg Twice Daily (BID) | BG00012 240 mg 3 Times Daily (TID) | Total |
|---|---|---|---|---|
| Mean | 38.5 ± 9.14 | 38.1 ± 9.11 | 38.8 ± 8.85 | 38.5 ± 9.03 |
| Sex: Female, Male(Participants) | Placebo | BG00012 240 mg Twice Daily (BID) | BG00012 240 mg 3 Times Daily (TID) | Total |
|---|---|---|---|---|
| Female | 306 | 296 | 306 | 908 |
| Male | 102 | 114 | 110 | 326 |
| Mean Expanded Disability Status Scale (EDSS) score(units on a scale) | Placebo | BG00012 240 mg Twice Daily (BID) | BG00012 240 mg 3 Times Daily (TID) | Total |
|---|---|---|---|---|
| Mean | 2.48 ± 1.241 | 2.40 ± 1.290 | 2.36 ± 1.188 | 2.42 ± 1.240 |
| Mean number of relapses within the previous 3 years(Number of relapses) | Placebo | BG00012 240 mg Twice Daily (BID) | BG00012 240 mg 3 Times Daily (TID) | Total |
|---|---|---|---|---|
| Mean | 2.5 ± 1.56 | 2.5 ± 1.44 | 2.4 ± 1.27 | 2.5 ± 1.43 |
| Mean number of relapses within the past 12 months(Number of relapses) | Placebo | BG00012 240 mg Twice Daily (BID) | BG00012 240 mg 3 Times Daily (TID) | Total |
|---|---|---|---|---|
| Mean | 1.3 ± 0.67 | 1.3 ± 0.67 | 1.3 ± 0.60 | 1.3 ± 0.65 |
| Time since first multiple sclerosis (MS) diagnosis(Years) | Placebo | BG00012 240 mg Twice Daily (BID) | BG00012 240 mg 3 Times Daily (TID) | Total |
|---|---|---|---|---|
| Mean | 5.8 ± 5.78 | 5.6 ± 5.39 | 5.1 ± 5.29 | 5.5 ± 5.49 |
| Mean number of gadolinium (Gd) enhancing lesions(Number of Gd enhancing lesions) | Placebo | BG00012 240 mg Twice Daily (BID) | BG00012 240 mg 3 Times Daily (TID) | Total |
|---|---|---|---|---|
| Mean | 1.6 ± 3.45 | 1.2 ± 3.30 | 1.2 ± 4.10 | 1.4 ± 3.64 |
Showing the first 100 of 160 sites across 29 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2007, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 3 years 4 months after primary completion. A results delay was requested in Oct 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dimethyl Fumarate
Multiple Sclerosis, Relapsing-Remitting →